FDA Scientists Reject HHS Peptide Policy Amid Safety Concerns
The Trump administration’s Department of Health and Human Services (HHS) issued a policy allowing compounding pharmacies to sell six unapproved peptides, including BPC-157 and TB-500, despite strong opposition from Food and Drug Administration (FDA) scientists. The move, championed by Health Secretary Robert F. Kennedy Jr., bypasses standard safety reviews and relies on enforcement discretion rather than formal approval. While HHS argues this reduces reliance on unsafe gray-market imports, FDA staff warned the substances lack clinical data for safety and efficacy. The policy includes limited safeguards, such as requiring ingredient sourcing from FDA-registered facilities, but critics argue it undermines the agency’s core mission of protecting public health.
Key points
- HHS issued a policy directing the FDA not to enforce rules against specialty pharmacies selling six unapproved peptides, including BPC-157, TB-500, and KPV.
- FDA scientific staff opposed the move, warning it could undermine the agency’s mission of keeping unproven health products off the US market.
- The policy includes guardrails, such as requiring pharmacies to use peptide ingredients from FDA-registered factories and collect side-effect data.
- Kennedy Jr. has called himself a 'big fan' of peptides and recently described using BPC-157 to treat a muscle injury.
- HHS initially sought a formal regulation deeming the peptides safe, but shifted to an enforcement discretion approach after FDA staff raised major safety concerns.
Background
This development follows a July advisory panel vote to loosen restrictions on peptides and a broader trend of federal funding cuts affecting US researchers. In 2023, the FDA added more than a dozen peptides, including BPC-157 and TB-500, to its list of substances that should not be compounded due to risks of allergic reactions, kidney damage, and tumor growth. The 2012 fungal meningitis outbreak linked to a Massachusetts compounding pharmacy also heightened FDA focus on compounding safety.
Why it matters
The policy shifts regulatory authority from the FDA to HHS, a rare move that could set a precedent for bypassing standard safety reviews. It may increase access to unproven treatments but also exposes the public to potential risks from substances lacking clinical data. The move reflects a broader tension between expanding patient access and maintaining rigorous safety standards in drug regulation.
What to watch
The FDA will likely monitor the implementation of the policy and the safety data collected from compounding pharmacies. HHS may face further scrutiny over its role in drug regulation, and the policy could influence future decisions on compounding and unapproved substances. Public health experts may continue to warn about the risks of untested peptides, while proponents may argue for expanded access.
- FDA scientists opposed Trump administration’s move to ease peptide access The Guardian
- RFK Jr. to Allow Broad Use of Unapproved Peptide Injections The New York Times
- AP report: FDA scientists opposed the Trump administration's move to ease peptides access PBS
- US Health Secretary Kennedy opens access to some unapproved peptides Reuters
- US to Allow Compounding of Six Peptides in Temporary Plan Bloomberg.com
Want the full story? Read the original reporting
Read on The Guardian